Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciencesMeet BioLizard’s...
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025...
A 4-week treatment with IMG-007 resulted in a mean reduction in eczema area and severity index (EASI) of 77% and...
Cannabix Technologies Inc. Cannabix Breath Collection Unit (“BCU”) with Breath Cartridge technology VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE)...
Appointment adds business, market and partner development expertise to FYR board Addition highlights FYR’s evolution into partner of choice for...
Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A...
VANCOUVER, British Columbia and LAS VEGAS, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV:...
Following $8.8m seed round, Biosphere aims to slash biomanufacturing’s capital costs by more than 50% OAKLAND, Calif., Jan. 09, 2025...
Company Making Additions to Executive Team and Advisory Board to Support Significant Commercial MomentumLONDON, Jan. 09, 2025 (GLOBE NEWSWIRE) --...
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE...
Divestment of Amwell Psychiatric Care intended to focus product portfolio on key growth initiatives Company reiterates guidance for 2024 BOSTON,...
FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical studies,...
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company...
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health...
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment...
ScriptMed Infusion will Accelerate New England Life Care's Patient-Centric Care and Scale Pharmacy OperationsBOWIE, Md., Jan. 09, 2025 (GLOBE NEWSWIRE)...
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a...
WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of...
WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on...
Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PTNEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics,...